Re-think Your Newcastle Disease Protection
US - At the forthcoming IPE show in Atlanta, Ceva will share with the poultry industry the outstanding results achieved through the use of VECTORMUNE® HVT-NDV in different parts of the world.
5 January 2012
2 minute read
By: VECTORMUNE® HVT-NDV, a CEVA innovative vaccine that protects against both Newcastle and Marek’s diseases is now available in several countries.
Newcastle disease has again become a top priority concern in recent years. Despite being recognised 86 years ago, conventional vaccines have limitations that mean that veterinarians struggle to control the disease, even today.
VECTORMUNE® HVT-NDV is able to bring to the industry strong advantages in both low and high challenge countries for Newcastle disease. Because maternally derived antibodies do not affect its efficacy, VECTORMUNE® HVT-NDV can be given in the hatchery, in-ovo or at one day of age. Based on a HVT vector, it provides homogenous lifelong protection for every chicken vaccinated.
Moreover, VECTORMUNE® HVT-NDV is extremely safe. It does not replicate in the respiratory tract and does not induce post-vaccination reaction.
Produced at the new state-of-the-art facility at the Ceva Biomune Campus in Kansas, VECTORMUNE® HVT-NDV is proving to be a major step forward in Newcastle disease protection in both the USA and around the world.
Further Reading
 |
- | Find out more information on Newcastle disease and Marek's disease by clicking here. |
IPE News & Information
Visit our full coverage of IPE here where ThePoultrySite team were fully represented.
